Private Management Group Inc. Reduces Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Private Management Group Inc. lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,273,997 shares of the company’s stock after selling 101,434 shares during the quarter. Private Management Group Inc. owned approximately 0.11% of Teva Pharmaceutical Industries worth $22,957,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its stake in Teva Pharmaceutical Industries by 273.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock worth $82,000 after buying an additional 3,323 shares during the last quarter. Gladstone Institutional Advisory LLC grew its position in Teva Pharmaceutical Industries by 847.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 143,939 shares of the company’s stock worth $2,594,000 after purchasing an additional 128,748 shares during the last quarter. Diversify Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $640,000. Diversify Advisory Services LLC grew its holdings in shares of Teva Pharmaceutical Industries by 95.3% during the third quarter. Diversify Advisory Services LLC now owns 19,859 shares of the company’s stock valued at $365,000 after buying an additional 9,693 shares during the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in shares of Teva Pharmaceutical Industries by 1,681.4% in the third quarter. GHP Investment Advisors Inc. now owns 32,065 shares of the company’s stock worth $578,000 after purchasing an additional 30,265 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TEVA shares. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. UBS Group lifted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Trading Up 0.1 %

TEVA traded up $0.01 during trading hours on Friday, reaching $18.45. The company’s stock had a trading volume of 7,100,136 shares, compared to its average volume of 5,049,047. The business’s 50-day moving average is $18.02 and its 200-day moving average is $16.92. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The stock has a market cap of $20.90 billion, a PE ratio of -47.32, a P/E/G ratio of 1.33 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.55 and a fifty-two week high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $3.99 billion. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.